Alteration of Cholesterol Metabolism by Metformin Is Associated With Improved Outcome in Type II Diabetic Patients With Diffuse Large B-Cell Lymphoma

Frontiers in Oncology

Xiang-Nan Jiang¹  Dong Sheng¹  Xiao-Qiu Li¹  Wei-Ge Wang¹  Yan Zhang¹  Xiao-Yan Zhou¹ 

[1]Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

[2]Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China

关键词: metformin;    cholesterol;    diffuse large B-cell lymphoma;    B-cell receptor;    type II diabetes;   

DOI  :  10.3389/fonc.2021.608238

来源: DOAJ

【 摘 要 】

Recent studies have demonstrated the benefits of metformin on patients with lymphomas. B-cell receptor (BCR)-PI3K-AKT pathway-dependent cholesterol synthesis may represent a positive feedback mechanism responsible for the pathogenesis of BCR-dependent diffuse large B-cell lymphomas (DLBCLs). Thus, restriction of lipid synthesis would affect the integrity of lipid-forming membranes and block the BCR signaling pathway. Our in vitro findings suggested that the blocking effect of metformin on BCR signaling pathway is possibly exerted via blocking the biosynthesis of cholesterol. A retrospective case-control study was subsequently conducted on type II diabetic patients with DLBCL who were on metformin. Metformin was identified to be associated with improved response rate and PFS in diabetic patients and appeared to be an effective therapeutic drug against DLBCL.

【 授权许可】

Unknown